EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy in Endometrial Cancer: Molecular Classification, Clinical Evidence, and Therapeutic Implications: A Narrative Review

Pablo Padilla-Iserte iD, Silvia Cabrera iD, Sonia Gatius Calderó iD, Ana de Juan Ferré, Katarina Majercakova, María Jesús Rubio-Pérez iD, Ignacio Romero, Maria Pilar Barretina-Ginesta iD, Manel Barahona Orpinell

Cancers · 24.05.2026 · 18 (11) · 1709

DOI: 10.3390/cancers18111709 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.05.2026. Verfasst von Pablo Padilla-Iserte und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, La Fe University and Polytechnic Hospital, Instituto de Investigación Sanitaria La Fe (IISLAFE), 46026 Valencia, …. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with increasing incidence and limited options in advanced disease. Molecular classification has redefined risk stratification and therapeutic decision-making, particularly with the incorporation of immunotherapy. This review provides a clinically oriented overview of immunotherapy in EC across molecular subgroups and treatment settings.

Methods

A narrative review was conducted using PubMed/MEDLINE, Embase, and Web of Science, focusing on clinical trials and studies with direct clinical relevance.

Results

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have demonstrated significant benefit in EC, particularly in mismatch repair-deficient (dMMR)/microsatellite instability–high (MSI-H) tumors, where durable responses are observed. In contrast, mismatch repair-proficient (pMMR) tumors show limited sensitivity to monotherapy and require combination approaches. Recent phase III trials have established chemoimmunotherapy as a first-line standard, with greater benefit in dMMR tumors and clinically meaningful improvements in pMMR disease. In the second-line setting, PD-1 inhibitor monotherapy is standard for dMMR tumors, while lenvatinib plus pembrolizumab is a key option for pMMR disease. However, responses remain heterogeneous and are not fully explained by MMR status alone.

Conclusions

Immunotherapy is a cornerstone in advanced EC management, guided by molecular classification. Key challenges include limited efficacy in pMMR tumors, lack of robust predictive biomarkers, and uncertainty in treatment sequencing. Future strategies should focus on biomarker-driven approaches and rational combinations.

Schlagwörter

Stichwörter der Autor:innen

PD-1/PD-L1endometrial cancerimmune checkpoint inhibitorsimmunotherapymismatch repair deficiencymolecular classification

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, La Fe University and Polytechnic Hospital, Instituto de Investigación Sanitaria La Fe (IISLAFE), 46026 Valencia, Spain.
  • Department of Pediatrics, Obstetrics and Gynaecology, University of Valencia, 46010 Valencia, Spain.
  • Department of Gynecologic Oncology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
  • Department of Pathology, Arnau de Vilanova University Hospital, Institut de Recerca Biomèdica de Lleida, University of Lleida, 25198 Lleida, Spain.
  • Department of Medical Oncology, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla (IDIVAL), 39008 Cantabria, Spain.
  • Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

ORCID-Profile: Pablo Padilla-Iserte, Silvia Cabrera, Sonia Gatius Calderó, María Jesús Rubio-Pérez, Maria Pilar Barretina-Ginesta

Zitieren

APA

Padilla-Iserte, P., Cabrera, S., Gatius Calderó, S., de Juan Ferré, A., Majercakova, K., Rubio-Pérez, M. J., Romero, I., Barretina-Ginesta, M. P., & Orpinell, M. B. (2026). Immunotherapy in Endometrial Cancer: Molecular Classification, Clinical Evidence, and Therapeutic Implications: A Narrative Review. Cancers, 18(11), 1709. https://doi.org/10.3390/cancers18111709

Vancouver

Padilla-Iserte P, Cabrera S, Gatius Calderó S, de Juan Ferré A, Majercakova K, Rubio-Pérez MJ, et al. Immunotherapy in Endometrial Cancer: Molecular Classification, Clinical Evidence, and Therapeutic Implications: A Narrative Review. Cancers. 2026;18(11):1709. doi:10.3390/cancers18111709

BibTeX
@article{PadillaIserte2026,
  author = {Padilla-Iserte, Pablo and Cabrera, Silvia and Gatius Calderó, Sonia and de Juan Ferré, Ana and Majercakova, Katarina and Rubio-Pérez, María Jesús and Romero, Ignacio and Barretina-Ginesta, Maria Pilar and Orpinell, Manel Barahona},
  title = {Immunotherapy in Endometrial Cancer: Molecular Classification, Clinical Evidence, and Therapeutic Implications: A Narrative Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1709},
  doi = {10.3390/cancers18111709}
}
Kostenlos starten →